Medicine
Volume 36, Issue 2 , Pages 78-81 , February 2008

Anorexia, cachexia and nutrition

References 

  1. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst. 1997;89:1763–1773
  2. Tisdale MJ. Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci. 2001;6:D164–D174
  3. Morley JE, Thomas DR, Wilson MM. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr. 2006;83:735–743
  4. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol. 2003;4:686–694
  5. Deboer MD, Marks DL. Cachexia: lessons from melanocortin antagonism. Trends Endocrinol Metab. 2006;17:199–204
  6. Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res. 2001;61:1432–1438
  7. Nahon JL. The melanocortins and melanin-concentrating hormone in the central regulation of feeding behavior and energy homeostasis. C R Biol. 2006;329:623–638
  8. Mancini DM, Walter G, Reichek N, et al. Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation. 1992;85:1364–1373
  9. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK. Tumour necrosis factor alpha in severe congestive cardiac failure. Br Heart J. 1993;70:141–143
  10. Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD. Systemic inflammation in patients with heart failure. Eur Heart J. 1998;19:761–765
  11. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704–711
  12. Genth-Zotz S, von HS, Bolger AP, et al. Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure. Am J Cardiol. 2002;90:1226–1230
  13. Brink M, Wellen J, Delafontaine P. Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism. J Clin Invest. 1996;97:2509–2516
  14. Wuyam B, Payen JF, Levy P, et al. Metabolism and aerobic capacity of skeletal muscle in chronic respiratory failure related to chronic obstructive pulmonary disease. Eur Respir J. 1992;5:157–162
  15. Skipworth RJ, Stewart GD, Ross JA, Guttridge DC, Fearon KC. The molecular mechanisms of skeletal muscle wasting: implications for therapy. Surgeon. 2006;4:273–283
  16. Tisdale MJ. Cancer anorexia and cachexia. Nutrition. 2001;17:438–442
  17. Deans C, Wigmore SJ. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005;8:265–269
  18. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med. 1995;152:1268–1274
  19. Wilson DO, Rogers RM, Sanders MH, Pennock BE, Reilly JJ. Nutritional intervention in malnourished patients with emphysema. Am Rev Respir Dis. 1986;134:672–677
  20. Lewis MI, Belman MJ, Dorr-Uyemura L. Nutritional supplementation in ambulatory patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1987;135:1062–1068
  21. Creutzberg EC, Wouters EF, Mostert R, Weling-Scheepers CA, Schols AM. Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition. 2003;19:120–127
  22. Springer J, Filippatos G, Akashi YJ, Anker SD. Prognosis and therapy approaches of cardiac cachexia. Curr Opin Cardiol. 2006;21:229–233
  23. Maltoni M, Nanni O, Scarpi E, Rossi D, Serra P, Amadori D. High-dose progestins for the treatment of cancer anorexia-cachexia syndrome: a systematic review of randomised clinical trials. Ann Oncol. 2001;12:289–300
  24. McMillan DC, Leen E, Smith J, et al. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol. 1995;21:531–534
  25. Preston T, Fearon KC, McMillan DC, et al. Effect of ibuprofen on the acute-phase response and protein metabolism in patients with cancer and weight loss. Br J Surg. 1995;82:229–234
  26. Barber MD, Fearon KC. Tolerance and incorporation of a high-dose eicosapentaenoic acid diester emulsion by patients with pancreatic cancer cachexia. Lipids. 2001;36:347–351
  27. Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer. 2000;36:177–184
  28. Hardman WE. Omega-3 fatty acids to augment cancer therapy. J Nutr. 2002;132:3508S–3512S
  29. Jho DH, Babcock TA, Tevar R, Helton WS, Espat NJ. Eicosapentaenoic acid supplementation reduces tumor volume and attenuates cachexia in a rat model of progressive non-metastasizing malignancy. J Parenter Enteral Nutr. 2002;26:291–297

PII: S1357-3039(07)00371-4

doi: 10.1016/j.mpmed.2007.11.004

Medicine
Volume 36, Issue 2 , Pages 78-81 , February 2008

Article Tools

* Image Usage & Resolution